Special Issue

Study on the Prevention and Treatment of Arbovirus

Message from the Guest Editors

Arboviral diseases are significant burdens on the health of individuals and economies throughout the tropics and subtropics. Vector-borne pathogens are transmitted to humans via the bite of an infected arthropod and then back to the mosquito during blood feeding. The epidemic has grown and become more frequent in both temperate and tropical regions. Vector control is still the primary control strategy for most of these diseases, and vaccines are available only for a handful of those, rendering susceptible populations at risk. With this Special Issue, we aim to discuss emerging concepts in vector-host interaction influencing pathogen emergence and other concepts in vector biology, pathogen transmission, and molecular interactions leading to pathogen transmission success. We also intend to discuss the influence of arthropod salivary proteins in modifying immune responses in the vertebrate host or in aiding/preventing pathogen replication, all in an effort to propose potential control strategies, including new therapeutic candidates such as vaccines and drug alternatives.

Guest Editors

Dr. Berlin Londono-Renteria

Department of Entomology, Kansas State University, Manhattan, KS 66505, USA

Dr. Guillermo Rua-Uribe

GEM-School of Medicine, University of Antioquia, Medellin, Colombia

Deadline for manuscript submissions

closed (31 May 2021)



an Open Access Journal by MDPI

Impact Factor 5.2 CiteScore 8.9 Indexed in PubMed



mdpi.com/si/41535

Vaccines
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

mdpi.com/journal/ vaccines





an Open Access Journal by MDPI

Impact Factor 5.2 CiteScore 8.9 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17.6 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2024).

